Scott Drake - AtriCure Independent Director
| ATRC Stock | USD 23.17 0.46 2.03% |
Director
Mr. Scott William Drake serves as Independent Chairman of the Board of AtriCure, Inc. Mr. Drake currently serves as the President and Chief Executive Officer of ViewRay, a publiclyheld medical device company with global operations in radiation therapy and imaging technologies. Mr. Drake was most recently the President, Chief Executive Officer, and member of the Board of Directors of The Spectranetics Corporation from 2011 to 2017. Spectranetics, acquired by Royal Philips in August of 2017, was a publiclyheld medical device company that developed, manufactured and distributed singleuse medical devices used in minimally invasive procedures within the cardiovascular system. Prior to joining Spectranetics, Mr. Drake served as Senior Vice President, Operations, of DaVita, Inc., a leading U.S. provider of kidney care and dialysis. Previously, Mr. Drake spent 17 years in several leadership positions within numerous healthcare business units at Covidien. From 2006 to 2009, he was President of Covidiens Respiratory and Monitoring Solutions Global Business Unit, a 1.5 billion business with 8, 000 employees. Mr. Drake has also served on the Board of Directors for The Zayo Group Holdings, Inc. since November 2018. Mr. Drake is Chairperson of the AdvaMed Radiation Therapy Sector and a board member of the Medical Device Manufacturers Association since 2018.
| Age | 50 |
| Tenure | 6 years |
| Address | 7555 Innovation Way, Mason, OH, United States, 45040 |
| Phone | 513 755 4100 |
| Web | https://www.atricure.com |
Scott Drake Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Drake against AtriCure stock is an integral part of due diligence when investing in AtriCure. Scott Drake insider activity provides valuable insight into whether AtriCure is net buyers or sellers over its current business cycle. Note, AtriCure insiders must abide by specific rules, including filing SEC forms every time they buy or sell AtriCure'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Drake over three weeks ago Acquisition by Scott Drake of 21021 shares of Farmer Bros subject to Rule 16b-3 |
AtriCure Management Efficiency
The company has return on total asset (ROA) of (0.0324) % which means that it has lost $0.0324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.06. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Valery Serdyukov | Si Bone | 72 | |
| Harald Ruf | Orthopediatrics Corp | 64 | |
| Jonathan Kennedy | Iradimed Co | 46 | |
| Elena Mikhaylova | Si Bone | 41 | |
| Viktoriya Nenadyshina | Si Bone | N/A | |
| Stan Erickson | Electromed | 66 | |
| Vladimir Alisov | Si Bone | 58 | |
| Vsevolod Cherepanov | Si Bone | 51 | |
| Erich Reinhardt | Varex Imaging Corp | 71 | |
| Christine Tsingos | Varex Imaging Corp | 59 | |
| Bernie Berry | Orthopediatrics Corp | 65 | |
| Andrey Dmitriev | Si Bone | 43 | |
| Lee Jones | Electromed | 60 | |
| Monty Allen | Iradimed Co | 65 | |
| Stephen Burns | Orthopediatrics Corp | 74 | |
| Michael Geraghty | Apyx Medical | 71 | |
| Saqib Iqbal | Si Bone | N/A | |
| William Eckles | Electromed | 42 | |
| Keith Valentine | Si Bone | 50 | |
| Walter Rosebrough | Varex Imaging Corp | 63 | |
| Jay Kunkel | Varex Imaging Corp | 58 | |
Management Performance
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0324 |
AtriCure Leadership Team
Elected by the shareholders, the AtriCure's board of directors comprises two types of representatives: AtriCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AtriCure. The board's role is to monitor AtriCure's management team and ensure that shareholders' interests are well served. AtriCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AtriCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Salvatore Privitera, CTO | ||
| Patricia Kennedy, Vice President General Manager - International | ||
| Deborah Yount, Chief Officer | ||
| JD CCEP, Chief Officer | ||
| CCEP CCEP, Chief Officer | ||
| Regina Groves, Independent Director | ||
| Scott Drake, Independent Director | ||
| Mark Collar, Independent Director | ||
| Valerie StorchWillhaus, Vice Communications | ||
| Michael Carrel, CEO and President and Director | ||
| Mark Lanning, Independent Director | ||
| Richard Johnston, Independent Chairman of the Board | ||
| Robert White, Independent Director | ||
| Sven Wehrwein, Independent Director | ||
| Angela CPA, Chief Officer | ||
| Elizabeth Krell, Independent Director | ||
| Andrew Lux, Sr. VP of Operations and Quality Assurance | ||
| Tonya SPHR, VP HR | ||
| Vinayak Doraiswamy, Chief Officer | ||
| Michael Hooven, Founder and Director | ||
| Karen Robards, Independent Director | ||
| Salvatore JD, Chief Officer | ||
| Justin Noznesky, Senior Vice President Marketing and Business Development | ||
| Douglas Seith, Chief Officer | ||
| Andrew Wade, CFO, Senior Vice President | ||
| Kristine Johnson, Independent Director | ||
| Amalio MD, Ex Officer |
AtriCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AtriCure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0324 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 48.37 M | ||||
| Shares Owned By Insiders | 3.07 % | ||||
| Shares Owned By Institutions | 96.93 % | ||||
| Number Of Shares Shorted | 3.2 M | ||||
| Price To Earning | 33.47 X |
Pair Trading with AtriCure
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AtriCure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AtriCure will appreciate offsetting losses from the drop in the long position's value.Moving together with AtriCure Stock
| 0.84 | NRC | National Research Corp | PairCorr |
Moving against AtriCure Stock
| 0.78 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.75 | NXL | Nexalin Technology | PairCorr |
| 0.67 | IRIX | IRIDEX Financial Report 9th of May 2024 | PairCorr |
| 0.41 | AGTI | Agiliti Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to AtriCure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AtriCure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AtriCure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AtriCure to buy it.
The correlation of AtriCure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AtriCure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AtriCure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AtriCure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for AtriCure Stock analysis
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is AtriCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.66) | Revenue Per Share 8.621 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) | Return On Equity (0.07) |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.